Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma is attractive because its lead antiviral TXM now has a clearer regulatory path, with an updated toxicology package targeted for resubmission by the end of 3Q26 and a U.S. clinical hold resolution expected by year-end, which could unlock the planned Phase 2a challenge study. The 1Q26 PIPE added $10.0M upfront and up to $60.0M in potential gross proceeds, supporting operations into 1Q27 and reducing the near-term cash overhang that often pressures clinical-stage biotechs. With 2Q26 cash of $5.0M, a narrower 2Q26 loss of $0.16 per share versus $(0.34) consensus, and expanding TXM positioning as a once-monthly influenza prophylactic plus pandemic-preparedness asset, the company offers meaningful upside if execution continues.

Traws Pharma is facing a weakened fundamental outlook because its lead influenza asset, tivoxavir marboxil, lost near-term validation after the MHRA’s negative review, while the FDA also kept the U.S. IND on clinical hold for toxicology concerns. The company’s planned revised MHRA package is not expected until the end of 3Q26, and even if accepted, the program remains dependent on additional regulatory progress, leaving limited visibility on a key value driver. At the same time, the COVID opportunity has shrunk materially, with Paxlovid sales falling to $186M in 1Q26 from $1.2B in 3Q25, while Traws’ April 2026 financing only provided $10.0M upfront and highlighted dilution and funding risk ahead of a 1Q27 overhang.